Ophidion, an early-stage biopharmaceutical company developing non-invasive therapeutics for neurodegenerative disorders, and Neuronasal, a clinical-stage biotechnology company focused on nose-to-brain delivery of therapeutics for CNS disorders, announced a strategic partnership on December 15th, 2025. According to a company press release, the partnership will see the companies co-develop therapeutic candidates for Parkinson’s disease, obesity, and diabetes.

Per the terms of the agreement, Ophidion will use its intravenous “Trojan-horse” carrier technology to deliver oligonucleotide payloads and peptide therapeutics across the blood-brain barrier. This process aims to improve brain exposures and clinical outcomes for several Parkinson’s-related molecular targets, as well as a single target for treating obesity and diabetes.

“We are excited to partner with Neuronasal and advance these therapeutics with our Central Nervous System (CNS)-delivery platform,” said Yacoub Habib, CEO, Ophidion, in the release. “Parkinson’s disease remains a major unmet need, and by tackling multiple targets simultaneously, we believe we can increase the probability of success and speed translation into patients. Additionally, improving the delivery of therapeutics to the brain for obesity and diabetes has the potential to produce better efficacy in this commercially attractive market.”

“Neuronasal is excited to add Ophidion’s brain delivery capability to our Parkinson’s disease developments; combining our expertise with Ophidion’s CNS delivery platform will enhance our clinical program for disease-modifying therapies,” said Thomas I. Bradshaw, CEO, Neuronasal, in the release.

According to the release, the partnership will span from proof-of-biology through IND-enabling studies. While details concerning upfront and development milestone payments were not disclosed in the release, the companies did announce plans to form a joint venture to advance programs through clinical development once each product reaches the IND stage.